<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Julia-Palacios N</submitter><funding>Generalitat de Catalunya</funding><funding>GENOMIT-4</funding><funding>PERIS</funding><funding>Asociación de Enfermos de Patologías Mitocondriales</funding><funding>CERCA Programe</funding><funding>Instituto de Salud Carlos III</funding><funding>Fundación Ana Carolina Diez Mahou</funding><funding>Departament de Salut de la Generalitat de Catalunya</funding><funding>European Union</funding><funding>Agència de Gestió d&amp;apos;Ajuts Universitaris i de Recerca</funding><pagination>fcaf348</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12484445</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>7(5)</volume><pubmed_abstract>Copper is indispensable for various metabolic processes, notably mitochondrial respiration. In humans, copper homeostasis hinges on transporters such as copper transporter 1 (CTR1), encoded by the &lt;i>SLC31A1&lt;/i> gene. Recently, bi-allelic mutations in &lt;i>SLC31A1&lt;/i> have been associated with a new neurodevelopmental disorder. This study presents clinical, genetic, and biochemical findings from 13 new cases across 10 families worldwide. RNA sequencing evaluated gene expression, and Western blotting assessed copper transporter 1 protein levels. Additionally, mitochondrial respiratory capacity was measured via high-resolution respirometry. Affected individuals exhibited a distinct clinical phenotype characterized by early-onset epileptic encephalopathy, severe neurodevelopmental delay and hyp</pubmed_abstract><journal>Brain communications</journal><pubmed_title>Clinical and molecular characterization of SLC31A1-related developmental and epileptic encephalopathy: insights from 13 new cases.</pubmed_title><pmcid>PMC12484445</pmcid><funding_grant_id>2021:SGR 01423</funding_grant_id><funding_grant_id>EJPRD22-123</funding_grant_id><funding_grant_id>FI18/00253</funding_grant_id><funding_grant_id>SLT002/16/00174</funding_grant_id><pubmed_authors>Hoenicka J</pubmed_authors><pubmed_authors>Codina A</pubmed_authors><pubmed_authors>Abd Elmaksoud M</pubmed_authors><pubmed_authors>Gaffney P</pubmed_authors><pubmed_authors>Palau F</pubmed_authors><pubmed_authors>Maroofian R</pubmed_authors><pubmed_authors>Bauer P</pubmed_authors><pubmed_authors>Anjum MN</pubmed_authors><pubmed_authors>Ortigoza-Escobar JD</pubmed_authors><pubmed_authors>O'Callaghan M</pubmed_authors><pubmed_authors>Alijanpour S</pubmed_authors><pubmed_authors>Muchart-Lopez J</pubmed_authors><pubmed_authors>Julia-Palacios N</pubmed_authors><pubmed_authors>Urreizti R</pubmed_authors><pubmed_authors>Ababneh F</pubmed_authors><pubmed_authors>Wierenga KJ</pubmed_authors><pubmed_authors>Webb BD</pubmed_authors><pubmed_authors>Baide-Mairena H</pubmed_authors><pubmed_authors>Garcia-Cazorla A</pubmed_authors><pubmed_authors>Houlden H</pubmed_authors><pubmed_authors>Zonic E</pubmed_authors><pubmed_authors>Cristian I</pubmed_authors><pubmed_authors>Munoz-Pujol G</pubmed_authors><pubmed_authors>Machado-Casas IS</pubmed_authors><pubmed_authors>Tyler M</pubmed_authors><pubmed_authors>Fayazi A</pubmed_authors><pubmed_authors>Tort F</pubmed_authors><pubmed_authors>Artuch R</pubmed_authors><pubmed_authors>Morrison J</pubmed_authors><pubmed_authors>Barba U</pubmed_authors><pubmed_authors>Cheema H</pubmed_authors><pubmed_authors>Carroll CJ</pubmed_authors><pubmed_authors>Urbaniak M</pubmed_authors><pubmed_authors>Paredes-Fuentes AJ</pubmed_authors><pubmed_authors>Ribes A</pubmed_authors><pubmed_authors>Bertoli-Avella AM</pubmed_authors><pubmed_authors>Santos-Ocana C</pubmed_authors><pubmed_authors>Gomez-Chiari M</pubmed_authors><pubmed_authors>Miryounesi M</pubmed_authors><pubmed_authors>Al-Sannaa N</pubmed_authors><pubmed_authors>Tonekaboni SH</pubmed_authors></additional><is_claimable>false</is_claimable><name>Clinical and molecular characterization of SLC31A1-related developmental and epileptic encephalopathy: insights from 13 new cases.</name><description>Copper is indispensable for various metabolic processes, notably mitochondrial respiration. In humans, copper homeostasis hinges on transporters such as copper transporter 1 (CTR1), encoded by the &lt;i>SLC31A1&lt;/i> gene. Recently, bi-allelic mutations in &lt;i>SLC31A1&lt;/i> have been associated with a new neurodevelopmental disorder. This study presents clinical, genetic, and biochemical findings from 13 new cases across 10 families worldwide. RNA sequencing evaluated gene expression, and Western blotting assessed copper transporter 1 protein levels. Additionally, mitochondrial respiratory capacity was measured via high-resolution respirometry. Affected individuals exhibited a distinct clinical phenotype characterized by early-onset epileptic encephalopathy, severe neurodevelopmental delay and hyp</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025</publication><modification>2026-05-04T03:17:33.357Z</modification><creation>2026-05-04T03:13:34.45Z</creation></dates><accession>S-EPMC12484445</accession><cross_references><pubmed>41040850</pubmed><doi>10.1093/braincomms/fcaf348</doi></cross_references></HashMap>